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Abstract
Background: The current paper reviews data from different sources to get a closer impression
on the psychometric and other methodological characteristics of the Aging Males' Symptoms
(AMS) scale gathered recently. The scale was designed and standardized as self-administered scale
to (a) to assess symptoms of aging (independent from those which are disease-related) between
groups of males under different conditions, (b) to evaluate the severity of symptoms over time, and
(c) to measure changes pre- and post androgen replacement therapy. The scale is in widespread
use (14 languages).
Method: Original data from different studies in many countries were centrally analysed to evaluate
reliability and validity of the AMS.
Results: Reliability measures (consistency and test-retest stability) were found to be good across
countries, although the sample size was sometimes small.
Validity: The internal structure of the AMS in healthy and androgen deficient males, and across
countries was sufficiently similar to conclude that the scale really measures the same phenomenon.
The sub-scores and total score correlations were high (0.8–0.9) but lower among the sub-scales
(0.5–0.7). This however suggests that the subscales are not fully independent.
The comparison with other scales for aging males or screening instruments for androgen deficiency
showed sufficiently good correlations, illustrating a good criterion-oriented validity. The same is
true for the comparison with the generic quality-of-life scale SF36 where also high correlation
coefficients have been shown.
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Methodological analyses of a treatment study of symptomatic males with testosterone
demonstrated the ability of the AMS scale to measure treatment effect, irrespective of the severity
of complaints before therapy. It was also shown that the AMS result can predict the independently
generated (physician's) opinion about the individual treatment effect.
Conclusion: The currently available methodological evidence points towards a high quality of the
AMS scale to measure and to compare HRQoL of aging males over time or before/after treatment,
it suggests a high reliability and high validity as far as the process of construct validation could be
pressed ahead yet. But certainly more data will become available, particularly from ongoing clinical
studies.
Background
The interest of clinical research in aging males increased in
recent years and thereby the interest to measure health-
related quality of life and symptoms. Aging men, how-
ever, are not as much aware of the fact as women that they,
too, undergo some kind of "transition" at the time when
women experience their menopausal transition – but
males overlook their symptoms usually. For example, the
various types of sweating do not show differences in fre-
quency between males and females in the course of aging
[1]. This applies more or less also for other symptoms – at
least in frequency [2].
The Aging Males' Symptoms (AMS) scale is a health-
related quality of life scale (HRQoL) and was originally
developed in Germany in 1999 [3]. The scale was
designed as self-administered scale to (a) to assess symp-
toms of aging (independent from those which are disease-
related) between groups of males under different condi-
tions, (b) to evaluate the severity of symptoms over time,
and (c) to measure changes pre- and post androgen ther-
apy [3]. It was developed in response to the lack of fully
standardized scales to measure the severity of aging symp-
toms and their impact on HRQoL in males, specifically
[4,5].
The AMS scale was internationally well accepted. Many
translations were done following international methodo-
logical recommendations (English, Dutch, French, Span-
ish, Portuguese, Italian, Swedish, Korean,, Thai, and
Japanese language), some are available only as simple for-
ward translation (Finnish, Flemish, Russian). These ver-
sions are available in a published form [4,6,7], on their
way to be published is a translations into Indonesian
language.
The evaluation of the AMS scale is simple and have been
published recently again [6] and there are norm values to
compare with [3,5]. Norm values of the standardized
scores (total score and three domain scores) however were
only published for Germany until now. In so far it is
important to compare the internal structure of the scale
among countries to get an impression whether one should
worry about compatibility if one intends to pool results of
clinical studies across countries.
Like in other QoL scales, it is a challenge to satisfy the
demands of a clinical utility and outcomes sensitivity, and
this in addition to the conventional psychometric require-
ments of test reliability and validity.
The aim of this paper is to present psychometric and clin-
ical data to discuss the methodologically relevant charac-
teristics of the AMS scale.
Methods
The development of the scale, instrument characteristics
(item selection, scaling), and norms and standardized
scores have been published elsewhere [3,5]. This applies
also for a few data that have been published on test-retest
stability and criterion-dependent validity [5].
During the last two years a number of smaller and larger
investigations were made from different groups to further
check methodological features of the scale. In other
words, this paper deals with a secondary analysis of data
gathered elsewhere and partly for other purposes than this
paper, however, we cannot see reason for a particular bias.
The original data were collected by the authors to set up a
comprehensive database suitable for the purposes of this
paper.
The majority are descriptive studies of community sam-
ples of aging males (all covering the age range 40 to about
70 years), some were planned as test-retest investigation
with a time interval of about two weeks, but there is only
one intervention study (before and after testosterone
treatment) completed yet. The latter study is not pub-
lished yet in detail but some methodologically relevant
results will be presented here.
A short description of the study groups follows:
Descriptive studies of aging males in Germany(aged 40–70
years)Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/77
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- 1996: 116 males with banal/minor health issues such as
common cold were recruited via GP's. This was the initial
study group for the development of the AMS scale
- 1997: A representative community sample of 958 males
was drawn for an opinion poll (EMNID) the AMS scale
was also applied.
- 2003: 4633 aging males of a representative community
sample participated in another opinion research (KDA)
that included the AMS scale.
Test-Retest (pilot) studies with community samples (aged
40–70 years): time interval between tests about two weeks
in all studies with a variation of a few days. The reason for
this time interval is: acceptable balance between the pos-
sibility that the respondent could still remember how he
answered the previous questionnaire and the other possi-
bility that the complaints changed in between.
- United Kingdom: A group of 96 healthy aging males
sampled from the community (2000)
- France: Convenience community sample; 21 males for
an orienting pilot study on test-retest stability (2002).
Convenience sample means that a group of repassing or
known males was investigated without efforts to formally
draw a random sample from a defined community.
- Spain: Convenience community sample; 33 males for an
orienting pilot study on test-retest stability (2002)
- Portugal: Convenience community sample; 20 males for
an orienting pilot study on test-retest stability (2002)
- Italy: Convenience community sample; 20 males for an
orienting pilot study on test-retest stability (2002)
- Sweden: Convenience community sample; 24 males for
an orienting pilot study on test-retest stability (2002)
- Thailand: Convenience community sample; 20 males for
an orienting pilot study on test-retest stability (2002)
- Korea: Convenience community sample; 25 males for an
orienting pilot study on test-retest stability (2002)
Intervention study (age range 17–83 years)
- Germany: 943 urology patients with diagnosed andro-
gen deficiency that were treated with testosterone depot
over 12 weeks; AMS measurement before and at the end
of treatment.
Using this database from different sources, we were able
to scrutinize many methodological characteristics of the
AMS scale to review most fundamental psychometric
characteristics as well validity in a clinical study setting.
Results and Discussion
Reliability
For all scientific measurements it is required to give evi-
dence of replicability (consistency) and test-retest reliabil-
ity. In contrast to systematic and random variation,
reliability gives an estimate of method-related measure-
ment error which should be low not to cover systematic
changes – due to treatment for example.
Table 1 shows the internal consistency measured with
Cronbach's Alpha. The consistency coefficients fell
between 0.7 and 0.9 across countries, time periods, and
total score as well the three subscales. This is indicative for
a very acceptable consistency of the AMS scale in our opin-
ion. Moreover, there is no evidence that the scale works
different in so many different countries in Europe and
Asia from this angle.
Table 1: Internal consistency coefficients (α) for the AMS scale across countries: total score and scores for the psychological, somatic, 
and sexual sub-scale. Community samples.
EUROPE ASIA
Overall Germany UK Rest Europe* Overall Thailand Korea
1996 1997 2003 2000 2002 2002 2002
N 5809 116 958 4633 96 118 45 20 25
Total score 0.90 0.88 0.86 0.90 0.90 0.88 0.92 0.79 0.94
Psychological score 0.83 0.82 0.76 0.83 0.84 0.76 0.87 0.58 0.89
Somatic score 0.82 0.84 0.79 0.82 0.85 0.77 0.83 0.70 0.87
Sexual score 0.81 0.80 0.72 0.81 0.80 0.80 0.77 0.62 0.76
* France, Spain,, Portugal, Italy, Sweden (about n = 20 each)Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/77
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The test-retest correlation coefficients (Pearson's correla-
tion) support the suggestion of a good temporal stability
of the total scale and its three sub-scales (table 2),
although most of the assessments across countries are
based on very small numbers. The intention of these pilot
studies was to get a preliminary idea about retest stability.
Larger sample sizes are required to permit final conclu-
sions for individual countries / languages.
The test-retest coefficients of the total score range between
0.8 and 0.9 across Europe and Asia. When it comes to the
subscales with much fewer items, the variation increased
and some of the coefficients went down to 0.5 (psycho-
logical scale: Spain, Italy; somatic scale: Portugal). Alto-
gether, the test-retest stability over a time period of two
weeks supports the notion of an acceptable reliability of
the total scale and their three sub-scales.
Although there is an impressive set of information cur-
rently available concerning the reliability of the AMS
scale, there are also limitations: Small sample sizes pre-
vent a final conclusion regarding test-retest reliability in
some of the languages the scale has been translated in. In
addition, further studies on consistency of the scale would
be welcome in some of the languages.
Validity
Similar to reliability that assesses the consistency of meas-
urement, the validity estimates if a QoL scale measures
what it intends to measure. But whereas reliability can be
determined straight forward with very few indicators, the
validity is almost always a continuous process (construct
validation). It is a process of accumulating evidence for a
valid measurement of what is purposed. Therefore, the
currently available data are already fairly comprehensive
and do pave the way for a focussed and continuing valida-
tion process.
Internal structure of the AMS across countries
The first step of validation is usually to demonstrate mul-
tivariately the internal structure ("dimensions") of a given
scale through factor analysis.
The first factorial analysis in 1996 was applied to identify
the dimensions of the scale. Three dimensions of symp-
toms/complaints were identified [3]: a psychological, a
somato-vegetative, and a sexual factor that explained
51.6% of the total variance (table 3). Since then, two large
community samples of aging males (also in Germany)
were performed and analysed for this paper, i.e. in 1997
and 2003. The loadings of the 17 items on the 3 factors are
astonishingly similar with those of the initial factor anal-
ysis. This suggests that the scale measures constantly the
same phenomenon over time in Germany. However,
there are two items that are not particularly helpful in
forming the sexual factor: The statement that the beard
growth decreased and the feeling to have passed the peak
of life. The latter had already a lower loading at the very
first analysis and the previous was intentionally included
into the scale on clinical considerations although there
was almost no loading. This indicates that item 12 ("Feel-
ing that you have passed your peak")and 14 ("Decrease of
beard growth") could be eliminated if a new standardiza-
tion is planned, currently however these items have to be
kept – otherwise standardization and norms will not be
applicable anymore.
An interesting piece of evidence for a good test character-
istics is the internal structure of the scale in males with
androgenic dysfunctions before treatment. The data came
from the baseline examination of the testosterone inter-
vention study by urologists in Germany (see methods).
The internal structure of the scale seems to be identical
with the "normal population", but the three factors
explain here more of the total variance (65% as compared
with around 55% in the normal population). This is
Table 2: Test-retest coefficients (Pearson's correlation coefficient r) for the AMS scale across countries: total score and scores for the 
psychological, somatic, and sexual sub-scale. Community samples.
EUROPE ASIA
Overall Germany UK France Spain Portugal Sweden Italy Overall Korea Thailand
N 3 1 6 1 0 2 9 6 2 1 3 32 0 2 4 2 0 4 52 5 2 0
Total score 0.86 0.86 0.91 0.85 0.80 0.74 0.88 0.79 0.91 0.90 0.87
Psychological score 0.77 0.81 0.81 0.82 0.50 0.67 0.69 0.54 0.87 0.85 0.78
Somatic score 0.83 0.85 0.91 0.71 0.89 0.45 0.94 0.76 0.87 0.87 0.81
Sexual score 0.82 0.80 0.81 0.88 0.74 0.67 0.84 0.98 0.80 0.77 0.68
* France, Spain,, Portugal, Italy, Sweden (about n = 20 each)Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/77
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indicative for a particular sensitivity to measure andro-
genic dysfunction.
The comparison of the internal structure between the
large German sample and the other countries is affected
by the small sample size in the latter. This may have intro-
duced much random error. Anyway, the structure found
in Germany (4 samples lumped together), UK, "Rest of
Europe" (France, Spain, Portugal, Italy, Sweden pooled),
and the two small samples from Asia (Thailand and
Korea) is – in average – in the same ballpark (table 4).
However, beside similarities there are also differences:
Three out of the five items originally belonging to the psy-
chological factor seem to be associated more with the
somatic factor in the Asian samples. There seems to be
also some evidence that the factors are not really inde-
pendent in the two Asian samples – whether this is real or
not cannot be decided with such small samples. In UK,
the somatic factor seems to have a slightly different pat-
tern: 3 out of 7 items seem to be more associated with the
psychological factor than the somatic. The item "increased
sweating" may have particular difficulties. The question is,
whether this is a problem of small numbers and random
error or reflection of remaining cultural differences.
Research with larger samples is suggested, on this occa-
sion also local norms of standardized score levels should
be determined which are currently available only for
Germany.
The possibly slight differences in the internal structure of
the AMS scale across country groups seen in table 4 sug-
gest further research but may not invalidate the compari-
son in clinical studies across countries or even prevent
pooling in multinational studies, because intra-individual
comparisons over time (before/after treatment) are the
main criterion which might not be affected very much.
However, it cannot be excluded that the real efficiency of
a given treatment measured with the AMS could be
diluted and thereby underestimated. But this remains
speculation until larger samples confirm the above
findings.
All the same, the factor analyses provide a confirmation of
the internal structure of the AMS scale across countries,
some less some more convincing.
Sub-scores and total score correlations
The relations among the sub-scales and the aggregate total
scale are patterns that are important in the methodologi-
cal assessment of a scale. In an ideal world, the correla-
tions between subscales (supposed to be independent)
would be closer to 0 than the correlations with the con-
Table 3: Germany: Internal structure of the AMS over time. Comparison of community samples with a sample of males with 
dysfunctions requiring treatment. Factor loadings only depicted if 0.5 or more in the sub-scales: psychological (psych), somatic (somat), 
and sexual sub-scale (sex).
COMMUNITY SAMPLES SAMPLE WITH DYSFUNCTION
Year 1996 1997 2003 2002
N 116 958 4633 943
Item Nr. Psych Somat Sex Psych Somat Sex Psych Somat Sex Psych Somat Sex
Burned out 13 0.8 0.6 0.7 0.7
Depressive, more 11 0.8 0.6 0.8 0.8
Irritability, increased 6 0.7 0.5 0.6 0.8
Anxious, more 8 0.7 0.7 0.7 0.8
Nervousness, more 7 0.6 0.6 0.7 0.8
Joint complaints, more 2 0.8 0.7 0.8 0.8
Sweating, increased 3 0.7 0.5 0.5 0.7
Sleep, need for more 5 0.6 0.6 0.6 0.6
Well-being, impaired 1 0.6 0.7 0.7 0.6
Sleep disturbances, more 4 0.6 0.6 0.5 0.6
Muscular weakness 10 0.5 0.5 0.6 0.5
Physical exhaustion 9 0.5 0.7 0.6 0.5
Sexual potency, impaired 15 0.9 0.8 0.9 0.9
Morning erections, less 16 0.9 0.8 0.9 0.9
Libido, disturbed 17 0.8 0.8 0.9 0.8
Passed peak 12 0.6 0.5 0.5
Decrease of beard growth 14 0.2 0.6Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/77
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struct of the aggregate total score to which all sub-scales
should significantly contribute. But that is theory; table 5
shows only a somewhat lower correlation among sub-
scales (0.5–0.7) as compared with correlation of sub-
scales with the total score (0.8–0.9). This is less different
than one would have wished. It suggests that the sub-
scales are not as independent from each other as one
would expect them to be – based on a factorial analysis
Table 4: International comparison of community samples: Internal structure of the AMS. Factor loadings only depicted if 0.5 or more 
in the sub-scales: psychological (psych), somatic (somat), and sexual sub-scale (sex). Germany: aggregate of samples 1996, 1997, and 
2003.
Germany United Kingdom Rest Europe Asia
N 5809 96 118 45
Item Nr. Psych Somat Sex Psych Somat Sex Psych Somat Sex Psych Somat Sex
Burned out 13 0.7 0.5 0.8
Depressive, more 11 0.8 0.7 0.7 0.6 0.6
Irritability, increased 6 0.6 0.8 0.7 0.7
Anxious, more 8 0.7 0.8 0.7 0.6
Nervousness, more 7 0.7 0.8 0.7 0.5
Joint complaints, more 2 0.8 0.5 0.5 0.8
Sweating, increased 3 0.5 0.7 0.6 0.8
Sleep, need for more 5 0.6 0.7 0.8 0.6
Well-being, impaired 1 0.7 0.6 0.5 0.6
Sleep disturbances, more 4 0.5 0.8 0.7 0.8
Muscular weakness 10 0.6 0.7 0.5 0.6 0.5
Physical exhaustion 9 0.6 0.7 0.6 0.8
Sexual potency, impaired 15 0.9 0.9 0.9 0.9
Morning erections, less 16 0.9 0.8 0.8 0.9
Libido, disturbed 17 0.9 0.9 0.8 0.8
Passed peak 12 0.5 0.6 0.5 0.6
Decrease of beard growth 14 0.6 0.5 0.8
Table 5: Domain score – total score correlations of the AMS scale across countries. Community samples.
DOMAINS
Psychological score Somatic score Sexual score
Germany (n = 5809)
Total score 0.8 0.9 0.8
Psychological score -- 0.7 0.5
Somatic score -- -- 0.5
UK (n = 96)
Total score 0.9 0.9 0.8
Psychological score -- 0.7 0.5
Somatic score -- -- 0.6
Other Europe* (n = 118)
Total score 0.8 0.9 0.8
Psychological score -- 0.6 0.5
Somatic score -- -- 0.6
Asia (n = 45)
Total score 0.9 0.9 0.8
Psychological score -- 0.8 0.7
Somatic score -- -- 0.6
* France, Spain,, Portugal, Italy, Sweden (about n = 20 each)Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/77
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with orthogonal factors. The situation was similar in Ger-
many, UK, Rest of Europe, and Asia. It is important to
realize how similar these correlation coefficients are
among countries/aggregates. This is suggestive of pretty
similar features of the AMS scale across the countries of
this review. It is even more important to underline that
this pattern is true both for the situation in the normal
population (community sample) and in patients with
apparent androgenic dysfunctions prior to treatment
(table 6).
Criterion-oriented validity: correlation with other scales
In fact, the comparison with other scales of similar pur-
pose is important. It is known from other quality of life
scales that comparisons with scales with similar purposes
are much more important than comparisons with so-
called objective parameters such as exercise tests, physio-
logical or chemical parameters – in our case with
hormones.
Health related quality of life should be validated against
quality of life measured with other generic QoL scales
(e.g., SF36), validated against specific instruments to
measure symptoms in aging males (e.g. Finnish Turku
scales), or with scales to screen for androgen deficiency
(e.g., ADAM, Smith's scale).
Finnish scales
Regarding validity of the AMS scale, a Finnish research
group observed a strong and statistically significant corre-
lation with their Turku 14-items scale for aging males (r =
0.8; n = 95), and similar promising results when compar-
ing with their own "3-Item-Scale" [5]. The two scales can
be regarded as measuring the same phenomena and this
speaks in favour of good test characteristics of the AMS
scale.
Androgen deficiency screening scales
In an investigation in 2003 we compared the AMS scale
with two screening instruments: The ADAM scale of Mor-
ley at al [8] and the Screener of Smith et al [9]. These two
scales were developed to screen males for a possible
androgen deficiency, i.e. to select persons for a lab test of
testosterone, for example.
A convenience sample of 150 German males aged 40–70
years was drawn from a population panel (not patients).
The three scales were administered for completion from
all participants. This study will be published in more
detail elsewhere.
To describe the ability of the AMS total score to predict the
results of each of the two other scales, a simple 2 × 2 table
was constructed: AMS negative (<27) or positive (27 and
more scoring points; the cut-off was arbitrarily chosen),
ADAM negative or positive (see [8]), and Smith's scale
"negative" (0–4 points; see [9]) or "positive" (two groups
of increasing "suspicion of hypogonadism" together: 5–
10+ points). The associations between the AMS categories
and the (ADAM) or (SMITH's) categories are significant.
The Cramer's V coefficients are as follows: AMS / ADAM
0.33, AMS / Smith's screener 0.31.
Using the above mentioned cut-off points of the scales,
the AMS predicted the results of the two other tests quite
good: AMS predicts ADAM: positive predictive value
(pPV) = 92%, negative predictive value (nPV) = 50%, spe-
cificity = 97%, and sensitivity = 29%. Thus, the AMS pre-
dicts well a positive screening result of the ADAM scale,
but less good negative screening results of the ADAM
scale. Similarly concerning the Smith's screener; the
respective values for the comparison of AMS vs. Smith's
screener are 65% (pPV), 49% (nPV), 87% (spec.), and
22% (sens.). The values for the prediction of ADAM
results regarding the Smith' screener results are somewhat
Table 6: Domain score – total score correlations of the AMS scale for a sample of community individuals and a sample of males with 
dysfunctions requiring treatment. Examples from Germany.
DOMAINS
Psychological score Somatic score Sexual score
Germany (n = 4633) Community sample
Total score 0.8 0.9 0.8
Psychological score -- 0.7 0.4
Somatic score -- -- 0.5
Germany (n = 943) Dysfunctional sample
Total score 0.9 0.9 0.8
Psychological score -- 0.7 0.6
Somatic score -- -- 0.6Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/77
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lower: 57% (pPV), 50% (nPV), 60% (sens.), and 46%
(spec.), respectively. Just for comparison, Morley [8]
reported for a positive ADAM result and a low bioavaila-
ble testosterone level (<70 ng/ml) a sensitivity of 88% and
a specificity of 60%.
These results showed again, that the AMS scale has a good
criterion-oriented validity, although the results can be dis-
cussed with a bit of reservation because both scales
(ADAM, SMITH's) have not be compared in the original
language. Just a simple German translation (no full cul-
tural adaptation was done) was the basis for this investi-
gation. Moreover, the AMS data could have been
combined with age and body mass index to match the
approach of the Smith's screener better. This and other
details will be published elsewhere.
Generic QoL scale SF36
Since the AMS scale is a health-related QoL scale, compar-
isons with other QOL scales are meaningful. The AMS
scale and the generic QoL instrument SF36 were applied
at the same time in 116 German males aged 40 to 70 with-
out serious health problems. The total score and the three
sub-scores of the AMS scale were compared with sub-
scales of the SF36 [5]. The AMS total sum-score and the
two sub-scales of SF36 were statistically significantly cor-
related: r = -0.49 (n = 116; p < 0.0001). The correlation of
the somatic sum-score of AMS and the somatic sum-score
of SF36 was sufficiently high (r = -0.54; p < 0.0001; n =
116) as well as the psychological sub-scales of both instru-
ments(r = -0.65; p < 0.0001; n = 116). The correlation is
inverse due to the fact that the sum-scores of the AMS
increase with numbers (intensity) of symptoms/com-
plaints and the sum-scores of SF36 increase with increas-
ing well-being/happiness. But there is no comparator in
the SF36 for the sexual sub-scale of the AMS [5].
Discriminative validity: detection of treatment effects
In this section, we summarize what information became
recently available regarding predictive or criterion-ori-
ented validity, i.e. the ability of the AMS scale to detect or
predict therapeutic effects or subjective judgments of this
effect by physicians. To this end, many clinicians use the
term "validity" and mean high utility for clinical work or
research. In so far it is important to address also this issue.
In the meantime the first androgen treatment study with
the AMS scale as outcome measure have been completed
(other clinical studies are under way elsewhere). It was a
simple open treatment study with testosterone depot per-
formed by the company Jenapharm in Germany. Specific
details will be published elsewhere. It is by no means the
intention to discuss the efficacy of testosterone treatment
or of a specific type. The aim is to check the evidence that
the AMS can detect "improvement of symptoms" and mir-
ror the subjective judgment of the treating physicians
about the effectiveness (not efficacy) of their treatment.
Therefore, methodologically relevant information will be
described here.
It is well established that men with androgen deficiency
react with a marked improvement of the health-related
quality of life (HRQoL) after testosterone treatment. It is
important to demonstrate that the AMS scale is able to
mirror changes of the HRQoL, i.e. that it can detect an
improvement of complaints after therapeutic interven-
tion. In the above mentioned study over 1000 men with
androgen-deficiency relevant complaints were followed-
up by urologists in their routine medical practice. After
some diagnostics (e.g. testosterone) they were treated with
testosterone over 12 weeks. The AMS scale was applied
before treatment and after 3 months of treatment. Data of
711/700 patients before /after therapy were available for
our analysis (50 years or older)
Figure 1 demonstrates that the increased mean AMS total
score at baseline (before treatment) decreased after 12
weeks under treatment, i.e. indicating an improvement of
complaints & HRQoL. This is also the case for the three
domains (data not shown). The absolute improvement of
symptoms during treatment was 15 scoring points of the
AMS in average. This is equivalent to 32% of the baseline
score. This is similar also for all three sub-scales (data not
shown). In other words, the AMS scale was fully able to
detect treatment effects (predictive value see further
down).
To answer the question whether the sensitivity of the AMS
scale is sufficient to detect even treatment-related changes
in patients with only mild or moderate symptoms as com-
pared with severe ones, the analysis was stratified by the
severity at baseline (Figure 2). An improvement of
complaints/QoL was seen in an increasing degree in
patients with mild, moderate and severe symptoms at
baseline. The relative improvement increases with the
degree of severity of symptoms at baseline, what fits the
general expectation. And there was still a positive treat-
ment effect in men with moderate or even mild
symptoms.
Figure 3 shows the capacity of the AMS scale to detect ther-
apeutic efficiency from another angle: the comparison
with norm values of the population. One can see that the
level of complaints in elderly patients before therapy is
very much shifted toward higher degree of severity (higher
AMS total score). After 12 weeks of testosterone treatment
the frequency distribution of patients with a certain sever-
ity of complaints became similar to the distribution in the
general population of aging males. This is re-assuring and
indicates that comparisons with norm values could beHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/77
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helpful for interpreting results of intervention studies. It is
another way to look at therapeutic efficiency with the
assistance of the AMS scale.
The AMS scale was also able to predict the independent
judgement of the urologists regarding the therapeutic
effect. The treating urologist assessed individually the
effectiveness of the hormone treatment in the above men-
tioned intervention study – without knowledge of the
results of the self-administered AMS questionnaire which
was only later analysed. Grouping the urologist's expert
opinion regarding treatment efficiency into two catego-
ries: effective (very effective and effective) and not effective
(little, no or negative effect) this alternative variable can
be used for a comparison with the AMS result (total score
only). We used two definitions for " treatment efficiency"
based on the change of the AMS total score between base-
line and treatment (as percent of the baseline total score):
no effectiveness = percent change (improvement of com-
plaints/quality of life up to +5% vs. up to +20% compared
with baseline. For the first cut-off off point (5% improve-
ment of total score) the positive predictive value was 89%,
the negative predictive value 59%, sensitivity (correct pre-
diction of a positive judgment of the physician concerning
therapeutic effectiveness) 96%, and specificity (correct
prediction of a negative assessment by the physician)
30%. In other words, the change of the AMS score fits well
with a positive judgement of the physician concerning
therapy efficiency, however predicts not as good a nega-
tive therapy assessment of the physician. The respective
data for the cut-off point "20% improvement of total
score" were 92%, 35%, 81%, and 61%. With higher cut-
Comparison of the mean AMS total scores before and after testosterone therapy in patients 50 years and older: mean (SD)  absolute scores (upper graph) and mean (SD) improvement (lower graph) compared with the baseline score: absolute and  (upper column) as percent (%) of the AMS score before therapy (lower column) Figure 1
Comparison of the mean AMS total scores before and after testosterone therapy in patients 50 years and older: mean (SD) 
absolute scores (upper graph) and mean (SD) improvement (lower graph) compared with the baseline score: absolute and 
(upper column) as percent (%) of the AMS score before therapy (lower column).
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points the positive predictive value remains stable at a
level of about 92%. This means, using 5% relative change
of the total AMS score as criterion, it would result in a high
positive predictive value but a lower negative predictive
value, very high sensitivity but low specificity. Still, the
results of the AMS scale and the judgment of the physician
regarding androgen treatment are in good agreement
according to our opinion.
In any case, it was not the aim of this exercise to suggest
'5% relative improvement' as a criterion for a new
"diagnostic test". The aim was only to demonstrate that
the AMS score can very well predict the clinical efficiency
of an androgen therapy in aging males with apparent
androgen deficiency. More details will be published else-
where, but it was our aim to present the methodological
essentials in this review paper. It should be just an exam-
ple to illustrate the capacity of the test and certainly not a
suggestion to use the scale as a substitute for the rather
complex medical judgement of the treating physician in a
clinical setting. However, it might be useful to apply the
standardized "objective" scale of the test in clinical studies
instead of a subjective judgement of a physician.
Conclusions
The AMS scale is a standardized HRQoL scale with good
psychometric characteristics. The use in many countries
offered the possibility to compare the test characteristics
across countries. Reliability measures (consistency and
test-retest stability) were found to be good in all countries
where data were obtained – however, some samples were
very small and therefore lumped together.
Average improvement of symptoms after therapy in four categories of severity at baseline Figure 2
Average improvement of symptoms after therapy in four categories of severity at baseline. Improvement of the total score 
after therapy – expressed as percent(%) of the value before therapy (baseline). Means and standard deviation of the relative 
improvement are depicted. The severer the symptoms at entry the higher the improvement of complaints/quality of life.
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The validity was measured in its various forms: The inter-
nal structure in healthy as well androgen deficient males
across countries was sufficiently similar to conclude that
the scale really measures the same phenomenon. The sub-
sores and total score correlations showed high coefficients
with the total score and less among the sub-scales. This
however indicates that the subscales are not fully inde-
pendent in practice.
The comparison with other scales for aging males or
screeners for androgen deficiency showed high correla-
tion coefficients, i.e. illustrating a good criterion-oriented
validity. The same is true for the comparison with the
generic QoL scale SF36 where also high correlation coeffi-
cients have been shown.
Methodological analyses of a testosterone treatment study
of symptomatic males demonstrated the ability of the
AMS scale to detect a treatment effect, irrespective of the
severity of complaints before therapy. It was also shown
that the AMS result can predict the independent (physi-
cian's) opinion about the individual treatment effect.
Thus, the currently available methodological evidence
points towards a high quality of the scale to measure and
to compare HRQoL of aging males over time or interven-
tion. It suggests a high reliability and high validity as far
as the process of construct validation could be pressed
ahead yet. But certainly more data will become available,
particularly from ongoing clinical studies. The latter is an
particular aim in the process of construct validation. It
Percentage (%) of patients in the four categories of severity of complaints according to AMS results at two points in time:  before therapy with testosterone and 12 weeks later after testosterone treatment Figure 3
Percentage (%) of patients in the four categories of severity of complaints according to AMS results at two points in time: 
before therapy with testosterone and 12 weeks later after testosterone treatment. The disturbed frequency distribution of 
severity before therapy (compared to the standard-left part) went back to the distribution in the "normal" standard population 
after therapy (right part). The population data came from the standardization of the AMS test [3,5]
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would be also interesting to invest more into the ability of
the scale to measure treatment effects regarding sexual
dysfunction specifically.
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